VALBIOTIS announces the First Patient First Visit in the international REVERSE-IT clinical study
VALBIOTIS announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study on TOTUM-63 to reduce Type 2 Diabetes risk factors
First development milestone payment of CHF 3 million from Nestlé Health Science
- The first subject, with fasting hyperglycemia, underwent the initial protocol medical visit prior to randomization at one of the study’s clinical investigation centers.
- The international REVERSE-IT study will include 600 subjects with altered glucose metabolism, spanning from elevated fasting glycemia to early, yet untreated, Type 2 Diabetes. Its primary endpoint is fasting glycemia and it will be led in more than 30 centers in France and abroad.
- This First Visit of the First Patient triggers a first milestone payment of CHF 3 million from Nestlé Health Science, thereby strengthening VALBIOTIS’ cash position.
La Rochelle, 15 July 2020 (5:40 CEST) VALBIOTIS (FR0013254851 – ALVAL /PEA/SME eligible), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the First Patient First Visit in the international Phase II/III REVERSE-IT clinical study designed to assess TOTUM-63 for the reduction of Type 2 Diabetes metabolic risk factors
Diary - News
All news VALBIOTIS announces the First Patient First Visit in the international REVERSE-IT clinical study 